European Hematology Association: A New Anti-CD22 CAR-T Immunotherapy Saved Life of Children With Leukemia

European Hematology Association: A New Anti-CD22 CAR-T Immunotherapy Saved Life of Children With Leukemia

June 16, 2018 B acute lymphoblastic leukemia (B-ALL) is a fatal blood cell tumor that is usually treated with chemotherapy or allogeneic hematopoietic stem cell transplantation (allo-HCT), and CD19-CAR-T cell therapy has been successful in treating refractory or relapsed (r/r)

European Hematology Association: Answering the Unmet Need in One of the Most Common Types of Lymphoma: It’s as Simple as A-D-C

European Hematology Association: Answering the Unmet Need in One of the Most Common Types of Lymphoma: It’s as Simple as A-D-C

June 16, 2018 Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Unfortunately, 40% of patients will relapse after or not respond to initial treatment resulting in poor outcomes especially if stem cell transplant is not

European Hematology Association: iNNOVATE Study: Ibrutinib Plus Rituximab for Patients With Waldenström’s Macroglobulinemia

European Hematology Association: iNNOVATE Study: Ibrutinib Plus Rituximab for Patients With Waldenström’s Macroglobulinemia

June 16, 2018 Waldenström’s Macroglobulinemia (WM) is a rare type of blood cancer. Since WM is rare, it is difficult to conduct large clinical studies and determine a standard treatment for the disease. Rituximab, a therapy used to treat other

European Hematology Association: Overall Survival Benefit of Obinutuzumab Over Rituximab When Combined With Chlorambucil in Patients With Chronic Lymphocytic Leukemia and Comorbidities

European Hematology Association: Overall Survival Benefit of Obinutuzumab Over Rituximab When Combined With Chlorambucil in Patients With Chronic Lymphocytic Leukemia and Comorbidities

June 15, 2018 Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody that is able to attack chronic lymphocytic leukemia (CLL) by binding and destroying malignant CLL cells. Rituximab is a non-glycoengineered type I anti-CD20 monoclonal antibody that also binds